Due to these advantages over first-generation EGFR inhibitors, afatinib also was investigated against cancer cells exhibiting abnormalities of the ErbB network such as NSCLC and breast cancer [47]. This evidence concerns the gene EGFR and non-small cell lung carcinoma.